Evidence map›Paper›PMID 41347506›Full record

ArticleMicrobiology spectrum2026

Earlier de-isolation of SARS-CoV-2-infected ICU patients using a novel viability PCR: a prospective cohort study.

Una Vojinović, Tom Schoenmakers, Ruben Deneer, Mathie P G Leers, Frank van Rosmalen, Stefan H M Gorissen, Wilhelmine P H G Verboeket-van de Venne, Walther N K A van Mook, Bas C T van Bussel, Paul Savelkoul and 3 more

Abstract read
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Una Vojinović *Department of Medical Microbiology, Infectious Diseases and Infection Prevention, Maastricht University Medical Center +, Maastricht, the Netherlands.ORCID 0009-0008-6304-1084
Tom Schoenmakers *Department of Clinical Chemistry & Hematology, Zuyderland Medical Center, Sittard-Geleen/Heerlen, the Netherlands.ORCID 0000-0002-1576-7832
Ruben DeneerDepartment of Clinical Chemistry & Hematology, Zuyderland Medical Center, Sittard-Geleen/Heerlen, the Netherlands.ORCID 0000-0002-6011-7783
Mathie P G LeersDepartment of Clinical Chemistry & Hematology, Zuyderland Medical Center, Sittard-Geleen/Heerlen, the Netherlands.ORCID 0000-0001-5186-5600
Frank van RosmalenDepartment of Intensive Care Medicine, Maastricht University Medical Center +, Maastricht, the Netherlands.ORCID 0000-0002-9522-3711
Stefan H M GorissenZuyderland Academy, Zuyderland Medical Center, Sittard-Geleen/Heerlen, the Netherlands.ORCID 0000-0003-3737-9053
Wilhelmine P H G Verboeket-van de VenneDepartment of Clinical Chemistry & Hematology, Zuyderland Medical Center, Sittard-Geleen/Heerlen, the Netherlands.ORCID 0000-0003-4980-0116
Walther N K A van MookDepartment of Intensive Care Medicine, Maastricht University Medical Center +, Maastricht, the Netherlands.ORCID 0000-0003-2398-8878
Bas C T van BusselDepartment of Intensive Care Medicine, Maastricht University Medical Center +, Maastricht, the Netherlands.ORCID 0000-0003-1621-7848
Paul SavelkoulDepartment of Medical Microbiology, Infectious Diseases and Infection Prevention, Maastricht University Medical Center +, Maastricht, the Netherlands.ORCID 0000-0002-3527-6950
Inge H M van LooDepartment of Medical Microbiology, Infectious Diseases and Infection Prevention, Maastricht University Medical Center +, Maastricht, the Netherlands.ORCID 0000-0002-5960-4357
Petra F G WolffsDepartment of Medical Microbiology, Infectious Diseases and Infection Prevention, Maastricht University Medical Center +, Maastricht, the Netherlands.ORCID 0000-0002-5326-3985
CoLaIC-consortium

Funding

ZonMw (Netherlands Organisation for Health Research and Development) 10430102110002
6 · The paper itself

Abstract

Intensive care unit (ICU) patients with COVID-19 are isolated until two subsequent SARS-CoV-2 PCR tests have become negative. The question is whether the viral RNA detected here represents intact or compromised viral particles. A viability PCR method detects only intact infectious viruses and disregards RNA from incomplete non-infectious viruses or RNA remnants. We hypothesize that the time to a negative PCR is shorter using the viability PCR compared to conventional SARS-CoV-2 PCR. Patients admitted to the ICU in the Maastricht University Medical Center within an ongoing prospective cohort were included, and respiratory samples were collected three times weekly. Samples were aliquoted for viability PCR into two aliquots, one of which was treated with propidium monoazide (PMA) to eliminate incomplete viruses. The PMA-untreated sample corresponded to the traditional SARS-CoV-2 PCR used in routine diagnostics. A mean time difference between viability and conventional PCR was estimated, assuming a negative binomial distribution. One hundred two ICU patients were included in the analysis. The time to a negative PCR test result differed significantly between viability PCR and conventional PCR (Paired Prentice-Wilcoxon test IMPORTANCE: This study demonstrated that, within patients, on average, viability PCR became negative 2.4 days earlier than conventional PCR, indicating that viability PCR could potentially assist in de-isolating patients 2.4 days earlier. Future use of this assay could thus aid in improving routine COVID-19 diagnostics and prognostics related to the timing of de-isolation. Additionally, future development of a similar approach for other respiratory viruses could be of interest.

Indexed as

COVID-19COVID-19 Nucleic Acid TestingPolymerase Chain ReactionSARS-CoV-2AdultAgedAged, 80 and overAzidesFemaleHumansIntensive Care UnitsMaleMicrobial ViabilityMiddle AgedPropidiumProspective StudiesAzidesPropidiumpropidium monoazideRNA, ViralCOVID-19de-isolationSARS-CoV-2viability PCR

Identifiers

PMID41347506
PMCPMC12772352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.